Mesoblast Limited (MESO) is a regenerative medicine company that develops and commercializes cell-based therapeutics. The company’s proprietary platform technology focuses on the use of Mesenchymal Precursor Cells (MPCs) for the treatment of various inflammatory and immune diseases. Through strategic partnerships and clinical trials, Mesoblast aims to transform the lives of patients by providing innovative and effective therapies.
